Synthis Therapeutics, Inc.
New York, NY Synthis
- UEI
- KC6RHFHRQAN6
- CAGE
- 7NWT8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- Bolt Bus 3, 101 6th Ave Fl 3, New York, NY 10013, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted tgfb therapy for cancer… | National Cancer Institute | $3,157,784 | |
| Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF)… | National Heart Lung and Blood Institute | $299,900 | |
| Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase… | National Cancer Institute | $509,975 | |
| Development of a t cell-targeted TGF-b antagonist that reverses immune suppression in melanoma patients | National Cancer Institute | $299,946 |
Quick answers
What is Synthis Therapeutics, Inc.'s UEI?
Synthis Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is KC6RHFHRQAN6.
What is Synthis Therapeutics, Inc.'s CAGE code?
Synthis Therapeutics, Inc.'s CAGE code is 7NWT8.
What is Synthis Therapeutics, Inc.'s primary NAICS code?
Synthis Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Synthis Therapeutics, Inc. located?
Synthis Therapeutics, Inc.'s physical address in SAM.gov is Bolt Bus 3, 101 6th Ave Fl 3, New York, NY 10013, USA.
Is Synthis Therapeutics, Inc. registered in SAM.gov?
Yes. Synthis Therapeutics, Inc.'s SAM.gov registration is active through January 27, 2027.
What is Synthis Therapeutics, Inc.'s most recent federal award?
Synthis Therapeutics, Inc.'s most recent federal grant award is In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted tgfb therapy for cancer… (R44CA291368), from National Cancer Institute, on September 18, 2024.
On GovTribe
See Synthis Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors